Premium
Chemohormonal therapy of metastatic prostate cancer. A pilot study
Author(s) -
Citrin Dennis L.,
Hogan Thomas F.,
Davis Thomas E.
Publication year - 1983
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19830801)52:3<410::aid-cncr2820520305>3.0.co;2-r
Subject(s) - medicine , diethylstilbestrol , prostate cancer , venous thrombosis , toxicity , thrombosis , oncology , cardiac toxicity , cancer , orchiectomy , surgery , hormone
Combined chemohormonal therapy of metastatic prostate cancer has not been previously evaluated in patients failing primary hormones (estrogens and/or orchiectomy). The combination of Adriamycin and high‐dose diethylstilbestrol diphosphate (Stilphostrol) was studied in 19 heavily pretreated patients, to document toxicity and patient acceptability. Major toxicity was myelosuppression, cardiac failure and venous thrombosis. Clinical improvement was noted in 10/16 (63%) of evaluable patients. Patients with pre‐existing cardiac disease or venous thrombosis are not suitable for this therapy.